Please login to the form below
Horizant
This page shows the latest Horizant news and features for those working in and with pharma, biotech and healthcare.
US shortage of GSK’s restless legs syndrome treatment Horizant
FDA blames contract manufacturer delays. Delays at GlaxoSmithKline's (GSK) contract manufacturer have caused a shortage in the US of restless legs syndrome treatment Horizant, according to the FDA. ... Then in November 2012, GSK and XenoPort agreed to
Latest news
-
GSK sales fall for first quarter of 2011
Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).
-
GSK Restless Legs Syndrome drug approved
GlaxoSmithKline and XenoPort have won marketing approval from the US Food and Drug Administration for Horizant, a treatment for moderate-to-severe primary Restless Legs Syndrome. ... Horizant's approval for the condition was based on two 12-week clinical
-
FDA rejects GSK and Xenoport's Horizant
GSK and XenoPort, have received a Complete Response letter from the US FDA relating to Horizant (gabapentin enacarbil). ... Horizant is developed from a variant of Pfizer's Nerontin (gabentin), used to control seizures in epilepsy patients.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch May 2016
399-616. Xenoport/ Arbor Pharmaceuticals. Corporate acquisition. Acquisition for $7.03 per share [60% premium]; includes Horizant [gabapentin] for restless legs.
Deal Watch May 2016
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
XenoPort appoints chief medical officer
Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome
XenoPort appoints chief medical officer
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Assessing the value of interim analyses in clinical trials
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- AZ’s Imfinzi combination shows promise in liver cancer
- Gilead’s Trodelvy set for EU approval in breast cancer
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Novo Nordisk settles US insulin pricing dispute for $100m
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- bluebird bio provides update on 2seventy bio spin-off
- Award-winning health agency 90TEN launches in the US
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
